key: cord-0861449-mwv394m9
authors: Lingor, Paul; Demleitner, Antonia F.; Wolff, Andreas W.; Feneberg, Emily
title: SARS-CoV-2 and neurodegenerative diseases: what we know and what we don’t
date: 2022-04-17
journal: J Neural Transm (Vienna)
DOI: 10.1007/s00702-022-02500-w
sha: 7447b98f07763ff23afc986b0c5b37099fa8826b
doc_id: 861449
cord_uid: mwv394m9

Infection of the CNS with the SARS-CoV-2 can occur via different routes and results in para- or post-infectious manifestations with a variety of neurological symptoms. In patients with neurodegenerative diseases, SARS-CoV-2 is often associated with a higher fatality rate, which is a relevant problem in increasingly older populations. Apart from the direct consequences of an infection in patients with neurodegenerative diseases, indirect consequences of the pandemic such as limited access to care facilities and treatment have negative effects on the course of these chronic disorders. The occurrence of long-lasting neurological symptoms after infection with SARS-CoV-2 indicates a prolonged impact on the CNS. However, while it is known that SARS-CoV-2 affects neuronal populations that are relevant in the pathogenesis of neurodegenerative diseases, it is yet unclear whether an infection with SARS-CoV-2 is sufficient to trigger neurodegeneration. Reflecting on the impact of SARS-CoV-2 on neurodegeneration, we provide a concise overview on the current knowledge of SARS-CoV-2-induced pathology in the CNS and discuss yet open questions in the field.

At the time of writing, almost 500 million people worldwide have been diagnosed with coronavirus disease 2019 , caused by the novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) (WHO 2022) . Early in the pandemic, it became clear that SARS-CoV-2 infections harbor the risk of developing neurological manifestations (Ababneh et al. 2020; Mao et al. 2020) . It has also become evident that SARS-CoV-2 infections have a negative effect on the outcome of patients with neurodegenerative diseases, predominantly studied in common neurodegenerative diseases such as Alzheimer's disease (AD) or Parkinson's disease (PD) (Hu et al. 2021 (Hu et al. , 2022 . In PD, an increased mortality rate was associated with SARS-CoV-2 infection, and an increased hospitalization and mortality rate has been shown for patients with AD (McAlpine et al. 2021; Zhang et al. 2020 Zhang et al. , 2021a . Data on the clinical outcome of SARS-CoV-2 infections on patients with other neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), or Huntington Disease (HD) are yet limited and will require further studies in the course of the pandemic (De Marchi et al. 2021; Musson et al. 2022) . Also, chronic neurological diseases such as multiple sclerosis with increased disability and a progressive course of disease have been associated with higher mortality rates (Prosperini et al. 2022; Barzegar et al. 2021) .

So far, different mechanisms have been considered as a cause of neurological symptoms or acceleration of existing neurological conditions during SARS-CoV-2 infection. These include direct effects of the virus on the central nervous system (CNS) by, e.g., entering the brain via nasal or oral routes and infection of neuronal populations (Meinhardt et al. 2021) and para-or post-infectious effects such as triggering inflammation and auto-immune reactions (Zubair et al. 2020; Franke et al. 2021) . Those effects of SARS-CoV-2 on the CNS have potential implications for the development of long-term neurological conditions including neurodegeneration. In addition, systemic effects during severe sepsis can trigger neurological symptoms (Heneka et al. 2020; Widmann and Heneka 2014) , and depend on the outcome and management of the acute disease.

In this review article, we will summarize recent evidence of effects of SARS-CoV-2 infection on the CNS and its implications for neurodegenerative diseases. We identified the existing evidence through author knowledge and Pub-Med searches from database inception, to March, 2022 using the search terms: "neurofilament", "neurodegeneration", "neurodegenerative diseases", "Parkinson disease", "Alzheimer disease", "amyotrophic lateral sclerosis", "dementia", "multiple sclerosis", "Covid-19", and "SARS-CoV-2".

When COVID-19 emerged, it became evident that the involved pathogen, the novel SARS-CoV-2 variant, was more transmittable between humans than its predecessor SARS-CoV-1 (Liu et al. 2020b ). Similar to its predecessor, SARS-CoV-2 uses the same densely glycosylated spike (S) protein on the viral surface to bind to the peptidase domain of the angiotensin-converting enzyme 2 receptor (ACE2) on mammalian host cells to enter cells yet with much higher affinity (Wrapp et al. 2020) . ACE2 is an extracellular enzyme with a transmembrane domain located toward the cell surface. Upon protease activation, soluble ACE2 is released into the extracellular space, where it physiologically processes angiotensin peptides as part of the angiotensin-renin pathway, while the transmembrane domain of ACE2 is internalized into the cell. During the internalization process, SARS-CoV-2 bound to ACE2 is either taken up by clathrin-coated vesicles or directly through involvement of the ACE2-specific transmembrane protease serine subtype 2 (TMPRSS2) . ACE2 is predominantly expressed in airway epithelia and lung parenchyma, kidney cells, small intestine, and vascular endothelia throughout the body, but also widely throughout the CNS (Deinhardt-Emmer et al. 2021) . Predilection sites of ACE2 in the brain are the posterior cingulate gyrus, motor cortex, olfactory bulb, middle temporal gyrus, substantia nigra, and the ventricles, where it is expressed in neurons, astrocytes, and oligodendrocytes (Xia and Lazartigues 2008; Chen et al. 2020) .

Loss of smell and taste were among the first CNS-related symptoms associated with SARS-CoV-2 infection, providing the early support for the hypothesis of direct entry of SARS-CoV-2 into the brain via the olfactory and oral mucosa. Although loss of smell is a common symptom in COVID-19 patients, its manifestation likely depends on the genetic variability of the virus and its host such as differences in ACE2 and TMPRSS2 expression Korber et al. 2020; Shang et al. 2020; von Bartheld et al. 2020; Strafella et al. 2020; Williams et al. 2020) . Studies with SARS-CoVinfected mice showed that virus antigen is found in the olfactory bulb and subsequently in connected brain regions such as the piriform cortex, basal ganglia, midbrain, and cardiorespiratory region of the medulla (Netland et al. 2008) . The detection of SARS-CoV-2 in human brain tissue has been challenging and likely depends on the severity of the CNS involvement. Whereas no evidence of SARS-CoV-2 was found in the brain of 19 infected patients without neurological symptoms (Hirschbuhl et al. 2021) , a post-mortem study of 33 SARS-CoV-2 patients with neurological symptoms found viral RNA in the nasal mucosa and to a lesser extend in the ophthalmic and oral mucosa as well as in the medulla oblongata (Meinhardt et al. 2021) . This study suggests that infection of the CNS by SARS-CoV-2 in patients with neurological symptoms is mediated by transsynaptic transmission across peripheral olfactory neurons to connected brain areas. Although this study did not detect SARS-CoV-2 in the carotid blood vessels and thus argued against a systemic infection via the blood stream, this route of infection cannot be completely ruled out. In a more detailed study of the olfactory mucosa, the virus was found in sustentacular and stem cells of the mucosa while absent from olfactory receptor neurons (ORN) (Butowt and von Bartheld 2020).

Alternative routes of CNS infection have been described across the blood-brain barrier (BBB), ACE2 expressing vascular endothelial cells, or indirect trafficking of the virus via blood leukocytes under increased permeability of the BBB (Zubair et al. 2020; Gomes et al. 2021) . By infecting inflammatory cells such as monocytes, macrophages, dendritic cells, and lymphocytes, the virus is able to initiate a cascade of cytokine release and an overwhelming activation of leucocytes which is responsible for subsequent cellular damage. Alternative explanations for SARS-CoV-2 CNS pathogenicity come from its association with auto-immune diseases (Tang et al. 2021 ). Its complex transcriptome, its ability to mimic human proteins, its ability to promote the generation of autoantibodies, and activate cytokine responses trigger auto-immune responses Kanduc 2021; Zhou et al. 2020c) . Neuroimmune manifestations such as Guillain-Barré syndrome (GBS), myasthenia gravis, acute disseminated encephalomyelitis (ADEM), or encephalitis suggest an autoantibody-mediated inflammatory response in certain neuronal populations (Toscano et al. 2020; Parsons et al. 2020; Zhou et al. 2020b; Muhammed et al. 2021; Restivo et al. 2020; Foresti et al. 2021) . In blood and CSF of SARS-CoV-2-infected patients with neurological symptoms, known autoantibodies against the NMDA-receptor or intracellular Yo-antigen were found, but also antibody binding on yet undetermined antigen epitopes on vessel endothelium, astrocytic proteins, neuropil of basal ganglia, hippocampus, or olfactory bulb from such samples was discovered (Watson et al. 2021; Franke et al. 2021; Mulder et al. 2021 ). This implies immunosuppressive therapy or plasmapheresis as a possible treatment for autoantibody-associated neurological symptoms.

Neurological symptoms have been described during and post-infection with SARS-CoV-2 Ellul et al. 2020) . The clinical presentation of neurological and encephalopathic findings ranged from mild headache and confusion over fluctuating levels of consciousness and extrapyramidal movement disorders (e.g., myoclonus) to seizures and coma (Garg et al. 2021; Romero-Sanchez et al. 2020) . Although the number of neurological complications might be lower in SARS-CoV-2 compared to other viruses, the scale of the pandemic renders the overall number of neurological complications and diseases a relevant socioeconomic burden (Ellul et al. 2020) . As direct evidence of viral DNA cannot be measured in the CNS of living patients, cerebrospinal fluid is used as an alternative source. However, only two case reports reported positive results for SARS-CoV-2 DNA in the CSF of COVID-19 patients with associated encephalitis, while larger retrospective studies of COVID-19 patients with neurological diseases had negative CSF measurements (Moriguchi et al. 2020; Zhou et al. 2020a; Destras et al. 2020; Neumann et al. 2020; Bellon et al. 2021 ). Nevertheless, several case studies confirmed neurological diseases associated with SARS-CoV-2 infection. Mild encephalopathies with transient symptoms such as altered consciousness (19.1% of 841 patients) or bradypsychia and disorientation (10.1% of 841 patients) were found to occur rather commonly often accompanied by findings of unspecific T2/FLAIR hyperintensity (35% of 20 patients) and ischemic infarcts (31% of 108 patients) in neuroimaging (Romero-Sanchez et al. 2020; Mahammedi et al. 2020; Radmanesh et al. 2020) . Severe COVID-19-associated encephalopathies including ADEM or acute necrotizing encephalopathies and poly(radiculo)neuropathies as GBS or other acute neuropathies (multifocal demyelinating or small fiber polyneuropathy) have also been described in several case reports with an estimated prevalence of 0.1-1% in western countries within 6 weeks of confirmed infection (Mahapure et al. 2021; Parsons et al. 2020; Shahali et al. 2021; Toscano et al. 2020; Camdessanche et al. 2020; Hayley and Sun 2021; Dixon et al. 2020; Poyiadji et al. 2020; Oaklander et al. 2022) . For some entities, a causative relationship to prior SARS-CoV-2 infection is less clear. For example, a large prospective observational study between January and May 2020 could not confirm a higher risk for GBS after SARS-CoV-2 infection (Luijten et al. 2021 ) and another study of 145.721 cases with COVID-19 showed that GBS had a low pooled prevalence (0.28% within the study cohort) compared to other neurological manifestations (Misra et al. 2021 ). Among the most common neurological complications in hospitalized patients with COVID-19 are cerebrovascular diseases which are likely associated with a pro-inflammatory hypercoagulable state in severe infection with elevated C-reactive protein, D-dimer, and ferritin (Lodigiani et al. 2020; Benussi et al. 2020) . Patients presented with ischemic and hemorrhagic stroke or venous thrombosis. In a recent meta-analysis of 145,634 COVID-19 patients, of which 89% were hospitalized, every third patient presented with a neurological manifestation (Misra et al. 2021) . A cross-sectional surveillance study in neurology, stroke, psychiatry, and intensive-care units in the UK in April 2020 included 125 patients of which 77 (62%) had a cerebrovascular event (74% ischemic, 12% intracerebral hemorrhage, and 1% vasculitis), while altered mental status was the second most common presentation (Varatharaj et al. 2020) . In 267 cases that were followed-up during that time COVID-19 associated stroke was mostly observed in younger adults, delirium was common in patients over 60 years and encephalopathy mostly in patients under 60 years treated on intensive-care units (Ross Russell et al. 2021) . Although less frequent, infections with SARS-CoV-2 have also been reported to result in movement disorders (Salari et al. 2021; Hull et al. 2021) .

Populations at risk for a deleterious outcome of COVID-19 have been identified early in the pandemic and encompass patients with higher age, male sex, obesity, diabetes, and other comorbidities (Williamson et al. 2020) . Patients with neurodegenerative disease are at particular risk, being mostly of higher age and presenting with many relevant comorbidities (Kitani-Morii et al. 2021) . Several studies have shown that a pre-existing neurodegenerative disease itself worsens SARS-CoV-2 infection outcomes. Data derived from metaanalyses and the UK Biobank have shown that dementia is an age-independent risk factor for a deleterious outcome of COVID-19 with increased disease severity and higher likelihood of death compared to non-demented control patients (Tahira et al. 2021; Liu et al. 2020a ). This effect has been confirmed for the subgroup of patients with AD, while vascular dementia was not associated with a higher risk (Zhang et al. 2021b ). The clinical presentation of COVID-19 infection in patients with concomitant dementia is often atypical with apathy and confusion or hyperactive delirium as leading symptoms, while cough, fever, or dyspnea are less frequent symptoms (Bianchetti et al. 2020; Harb et al. 2021; Mendes et al. 2021; Rebora et al. 2021; Hariyanto et al. 2021 ). In addition, delirium is an independent factor for worsening the outcome of SARS-CoV-2 including increased fatality (Rozzini et al. 2020; Garcez et al. 2020; Mendes et al. 2021) . In most retrospective analyses, a higher case fatality rate has been reported in patients with PD. Particularly, PD patients with longer disease duration and higher age show a high mortality rate of 21-40% during SARS-CoV-2 infections in different cohorts in Italy, the US, and Germany and independent of age, sex and ethnic background (Antonini et al. 2020; Zhang et al. 2020; Scherbaum et al. 2021 ). On the other hand, some studies with smaller sample sizes recruiting patients in tertiary referral centers in Europe and Italy did not find an increased mortality rate in PD nor dementia compared to demographically matched controls (Huber et al. 2021; Fasano et al. 2020) .

Data on other neurodegenerative diseases are less extensive. A study using the US veteran database and 699 patients with amyotrophic lateral sclerosis (ALS) found an increased risk of COVID-19 related death in this cohort (Galea et al. 2021) . In a Scottish cohort of 1062 patients with motor neuron disease, 77.7% of whom were diagnosed with ALS, allcause mortality remained unaffected in 2020, though specific mortality rates of individuals diagnosed with COVID-19 are not reported (Glasmacher et al. 2021) . Interestingly, C9orf72 repeat expansions of intermediate length, a mutation often found in cases of familial ALS and frontotemporal dementia (FTD), have been associated with severe COVID-19 requiring mechanical ventilation (Zanella et al. 2021) . Multiple sclerosis itself has not been associated with a severe course of disease, whereas increased disability and a progressive course of the disease, which is mainly mediated by neurodegenerative processes, have (Prosperini et al. 2022; Barzegar et al. 2021) . Future prospective studies including all healthcare services may shed light on the actual risk of patients with neurodegenerative disorders.

Besides the direct effect of an infection with SARS-CoV-2 on patients with neurodegenerative diseases, the impact of the global COVID-19 pandemic on these patients due to disruptions in the medical care is equally alarming. Since onset of the global pandemic in late 2019, symptoms such as anxiety, depression, and sleep disturbances have been found to have increased in the general public (Thygesen et al. 2021; Bauerle et al. 2020) . This is in line with cross-sectional data from more than 5000 patients with PD that revealed worsening of motor (43%) and especially non-motor (52%) symptoms since pandemic onset (Brown et al. 2020) . Home confinement and other disease control measures aiming at reduction of contacts are likely to contribute to a diminished physical activity in PD patients (Leavy et al. 2021 ) and foster the discontinuation of medical treatments, such as multimodal complex treatment or levodopa/carbidopa intestinal gel (LCIG) set-ups Wolff et al. 2022) . Disruptions were furthermore observed to impact clinical trials, due to difficulties in recruitment, initiation and monitoring (Lorusso et al. 2020 ) which will impact the development of future therapeutic options. Although adaptions such as implementation of remote monitoring and remote study endpoints have been made, they need to be expanded in the future (Snider and Holtzman 2021).

After acute infection with SARS-CoV-2, some of the associated symptoms can persist or additional symptoms can emerge. The British National Institute for Health and Care Excellence (NICE) distinguishes on one hand ongoing symptomatic COVID-19, defined as persistence of COVID-19-related signs and symptoms up to 12 weeks after infection, from the post-COVID-19 syndrome, defined as the persistence or occurrence of COVID-19-related symptoms 12 weeks after infection ( Fig. 1) (NICE 2022). The term "long-COVID" refers to the entirety of symptoms after an acute SARS-CoV-2 infection independent of time and duration and can be considered a disability under the Americans with Disabilities Act (ADA) since July 2021 (Centers for Disease and Prevention 2021; HHS.gov 2021). Patients suffering from post-COVID-19 syndrome may present with a volatile cluster of symptoms in any system of the body. These may include typical COVID-19-related symptoms such as loss of smell or dyspnea, but also include neurological symptoms, such as cognitive impairment, dizziness, and delirium (NICE 2022). Longitudinal assessment of 9751 patients with COVID-19 found the persistence of COVID-19-related symptoms in 72.5% of the cases after discharge (follow-up range from 29 to 234 days), most prominently shortness of breath or dyspnea (36.0%), and fatigue or exhaustion (40.0%) (Nasserie et al. 2021; Lara et al. 2020) . Particularly, the persistence of fatigue or muscle weakness correlated with the need of supplemental oxygen or the need of invasive and non-invasive breathing assistance in hospitalized COVID-19 patients 6 months after discharge (Huang et al. 2021 ). Both, the pandemic itself, and a previous infection with SARS-CoV-2 have been linked to an increase in distress and depression in the general public (Ramiz et al. 2021; Nasserie et al. 2021) . In particular, patients with preexisting neurodegenerative or chronic neurological diseases are at special risk for this development. Patients with dementia, AD, PD, and multiple sclerosis have been found to suffer from worsening of pre-existing symptoms and de-novo development of neuropsychiatric symptoms, e.g., anxiety and cognitive decline (Lara et al. 2020; Boutoleau-Bretonniere et al. 2020; Wei et al. 2022; Salari et al. 2020; Shalash et al. 2020; Wolff et al. 2022; Haji Akhoundi et al. 2020 ). This long-lasting impact of an infection with SARS-CoV-2 has resulted in the need for an implementation of a medical care structure for these patients (Gemelli Against 2020).

The association of neuropsychiatric symptoms with SARS-CoV-2 infection raises the question about the potential long-term impact of the virus on the CNS, its molecular basis, and the potential risk of neuronal damage associated with subsequent development of neurodegenerative diseases. During SARS-CoV infection, there is evidence of scattered degeneration of neurons as a sign of neuronal hypoxia/ischemia (Gu et al. 2005) . Sepsis itself has longterm consequences on the brain often associated with delirium and even cognitive decline later in life. Several mechanisms have been discussed to cause neuronal damage during sepsis. First, decreased blood flow caused by reduction in peripheral vascular tone and diminished cardiac output alters brain circulation. Altered microcirculation of the brain, possibly also through an impaired autoregulation caused by increased CO 2 levels, leads to detachment of pericytes from the basal lamina and increased permeability of the BBB (Nishioku et al. 2009; Barichello et al. 2021) . Sepsis triggers the peripheral innate immune system with an increased secretion of TNF-alpha and interleukins causing endothelial cell damage, disintegration of intracellular junctions, and increased permeability of the BBB. Invasion of T-lymphocytes and macrophages via the BBB activates microglia and astrocytes leading to cerebral cytokine, chemokine, and nitric oxide release, which causes neuronal dysfunction and ultimately cell death (Heneka et al. 2020; Widmann and Heneka 2014) . A well-established indicator for neuronal damage is the increase of blood or CSF levels of neurofilament light chain (NfL), which is a structural protein and part of the cytoskeleton of long axons. An increase in neurofilament levels has been related to unspecific neuronal damage that can be caused by neuroinflammation, neuronal ischemia, or neurodegeneration (Khalil et al. 2018) . Several studies assessed neurofilament levels in SARS-CoV-2 patients. CSF and blood NfL levels were elevated in patients with severe disease and concomitant neurological symptoms Paterson et al. 2021) . Another study evaluated blood NfL levels of 47 SARS-CoV-2 patients at admittance to hospital and showed that a higher baseline NfL level is a negative predictor of survival (Aamodt et al. 2021 ). Blood NfL was increased in the acute phase of 48 severe and 28 moderate SARS-CoV-2 cases, while after a 6-month follow-up NfL was normalized (Kanberg et al. 2021) . To predict the extent of neuronal damage in a cohort of 142 hospitalized patients with COVID-19, Prudencio et al. measured serum NfL at time of hospitalization and at multiple follow-ups (Prudencio et al. 2021) . Higher baseline NfL levels indicated worse clinical outcome, while over time NfL levels stayed constant or fluctuated, without a clear correlation to clinical symptoms. Although neurofilaments are an indicator of neuronal damage, it is not yet clear if their elevation indicates a risk for long-term neurodegeneration. To further support neuronal loss, diminished gray matter within the limbic cortical areas with direct neuronal connectivity to the primary olfactory system has been recently described in longitudinal brain imaging after COVID-19 infection (Douaud et al. 2021) .

Further evidence of a potential risk for the development of neurodegenerative diseases comes from case reports describing patients with akinetic-rigid parkinsonism following infection with SARS-CoV-2. In addition to improvement of symptoms either under Levodopa/Carbidopa-treatment or spontaneously, all patients displayed abnormal imaging findings, such as decreased dopamine transporter density in dopamine transporter scan or decreased dopamine uptake in 18 F-DOPA PET (Cohen et al. 2020; Faber et al. 2020; Mendez-Guerrero et al. 2020) . It remains uncertain, if these patients developed the clinical findings de-novo or if a subclinical PD emerged after worsening through severe COVID-19. Causal links of viral infections to neurodegenerative diseases have been drawn since the influenza pandemic in 1918, which is assumed to have caused numerous cases of postencephalitic parkinsonism (Kim et al. 2015; Hoffman and Vilensky 2017; Bigman and Bobrin 2018) . This theory was further fueled by the fact that the substantia nigra represents a potential target for neurovirulent influenza A viruses (Takahashi et al. 1995) . This is also true for coronaviruses, which have been shown to accumulate in the nucleus subthalamicus and the substantia nigra after infection in mice (Fishman et al. 1985) . Furthermore, elevated titers of antibodies directed against coronaviruses have been found in patients with PD (Fazzini et al. 1992 ). ACE2 has not only been found to be expressed by midbrain dopaminergic neurons, but dopaminergic neurons were also permissive for an infection with SARS-CoV-2 in-vitro . Further evidence for the involvement of the midbrain during COVID-19 was added by the fact that post-mortem analysis of patients with COVID-19 revealed activated microglia and cytotoxic T-lymphocytes in the brainstem and cerebellum (Matschke et al. 2020) . By infiltration of viruses to the CNS, neuroinflammation can be triggered, resulting in a disruption of the BBB, microglia activation, and clustering of microglia around (dopaminergic) neurons, as well as pro-inflammatory cytokine release. This is thought to result in a vicious circle of self-driven neuroinflammation, eventually resulting in neurodegeneration (Limphaibool et al. 2019) . In PD, there is strong evidence suggesting alpha-synuclein pathology propagates from the olfactory bulb and/or the gut to the brain, which is associated with early non-motor symptoms such as olfactory disfunction and obstipation (Braak et al. 2003; Haehner et al. 2011) .

Olfactory dysfunction, in particular loss of smell, is also a common symptom of COVID-19. ACE2 and TMPRSS2 have been shown to be expressed in human olfactory mucosa and therefore pose a possible entry site of SARS-CoV-2 to the brain, which is shared by alpha-synuclein pathology (Fig. 2; Brann et al. 2020) . Additionally, viral infections were found to increase alpha-synuclein expression levels in rodents and to induce the formation of cytotoxic alpha-synuclein aggregates (Beatman et al. 2015; Bantle et al. 2019) . Whether and in what way these findings might contribute to the development of PD is unknown. Furthermore, SARS-CoV-2 has been shown to also influence other proteins involved in neurodegenerative diseases such as AD: the expression of SARS-CoV-2 spike protein S has been linked to an increased spreading of Tau and cytosolic prions in-vitro and further prompted the aggregation of these proteins . A shift in localization of Tau from axons to the soma and hyperphosphorylation of Tau, both hallmarks of early stages of tauopathy, have been observed in SARS-CoV-2-infected neurons, resulting in cell death in 3D human brain organoids (Ramani et al. 2020 ). In Fig. 2 SARS-CoV-2 and neurodegenerative diseases. a Clinical presentation: SARS-CoV-2 infection leads to neurological symptoms and disorders (e.g., loss of smell, altered mental status, and stroke), severe sepsis, or worsening of neurodegenerative diseases. Whether SARS-CoV-2 induces neurodegenerative disorders is unknown. b-d Cellular and molecular mechanisms. b SARS-CoV-2 enters the brain via the nasal and oral mucosa and affects multiple brain regions, also those involved in neurodegenerative disorders. Systemic inflammation leads to dysfunction of the BBB and neuroinflammation. c Activation of microglia, astrocytes, and pro-inflammatory cytokines in the brain may trigger neuronal damage and release of NfL. d Neuronal damage by SARS-CoV-2 could be a potential risk for the development of neurodegeneration associated with proteinopathy, such as PD, AD and ALS. PD Parkinson's disease, AD Alzheimer's Disease, ALS amyotrophic lateral sclerosis, NfL neurofilament light chain, Tdp-43 TAR DNA-binding protein 43, a-Syn alpha-synuclein, Tau Protein Tau (Created with https:// biore nder. com/) Amyotrophic lateral sclerosis (ALS), the main pathological protein found aggregated in the cytoplasm of neurons leading to progressive degeneration of motor neurons is TAR DNAbinding protein 43 . In 10% of ALS cases, a known gene mutation underlies the disease, while in the majority of sporadic ALS patients, a multi-hit hypothesis of internal and external factors including environmental risk factors has been considered (Brown and Al-Chalabi 2017). A viral infection of specific neuronal populations such as motor neurons might lower the threshold for developing TDP-43 pathology as proposed in the multistep hypothesis for ALS (Chio et al. 2018) . In summary, there is growing evidence of COVID-19 associated neuropathological effects and SARS-CoV-2 may be impacting many pathways involved in the pathogenesis of neurodegenerative diseases. Whether this is sufficient to induce neurodegeneration and whether the human nervous system is able to counteract and regenerate is subject of ongoing research. Longitudinal data will be needed to evaluate the relevance of this impact on patients diagnosed with COVID-19.

This short review summarizes molecular and clinical evidence of CNS affection by the SARS-CoV-2 virus with particular reference to neurodegenerative disorders. Many questions, however, prevail. Although it is known that COVID-19 can cause neuronal damage as indicated by increased neurofilament levels, it is unresolved whether the CNS is able to recover completely or only partially from this damage and what the delay of such a recovery might be. Even less clear is whether such damage to the CNS triggers neurodegenerative diseases and with which latency the (clinical) onset of such diseases might be expected. Which genetic predispositions or environmental factors could modulate these outcomes? Are all viral strains/variants of concern equally dangerous in this regard? We also do not know whether long-COVID or post-COVID-19 syndrome predisposes to such potential long-term consequences. We know that vaccination against SARS-CoV-2 is a powerful means to prevent a severe course of disease in the general public (Thompson et al. 2021; Lin et al. 2022; Rosenberg et al. 2022; Hippisley-Cox et al. 2021) . Data on the safety and effectiveness of the available vaccines in the vulnerable population of patients with neurodegenerative diseases are lacking and urgently needed . It is also not clear to date whether vaccination also prevents potential neurodegeneration as sequelae of COVID-19 and what the role of different vaccines may be. Only longitudinal studies with large cohorts and appropriate controls will be able to solve these questions in the future (Horn et al. 2021 ).

Funding Open Access funding enabled and organized by Projekt DEAL.

The authors declare no competing financial or nonfinancial interests related to this work.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/. 

COVID-19 may induce Guillain-Barre syndrome

The spatial and cell-type distribution of SARS-CoV-2 receptor ACE2 in the human and mouse brains

The multistep hypothesis of ALS revisited: the role of genetic mutations

A case of probable Parkinson's disease after SARS-CoV-2 infection

COVID-19 rapid guidline: managing the long-term effects of COVID-19

Accelerated early progression of amyotrophic lateral sclerosis over the COVID-19 pandemic

Early postmortem mapping of SARS-CoV-2 RNA in patients with COVID-19 and the correlation with tissue damage

Systematic SARS-CoV-2 screening in cerebrospinal fluid during the COVID-19 pandemic

COVID-19-related acute necrotizing encephalopathy with brain stem involvement in a patient with aplastic anemia

Smith SM (2021) Brain imaging before and after COVID-19 in UK Biobank

Neurological associations of COVID-19

Coronavirus disease 2019 and Parkinsonism: a non-post-encephalitic Case

COVID-19 in Parkinson's disease patients living in Lombardy, Italy

Cerebrospinal fluid antibodies to coronavirus in patients with Parkinson's disease

Infection of the basal ganglia by a murine coronavirus

COVID-19 provoking Guillain-Barre syndrome: The Bergamo case series

High frequency of cerebrospinal fluid autoantibodies in COVID-19 patients with neurological symptoms

Infection rate, mortality and characteristics of veterans with amyotrophic lateral sclerosis with COVID-19

Delirium and adverse outcomes in hospitalized patients with COVID-19

Encephalopathy in patients with COVID-19: a review

Post-COVID-19 global health strategies: the need for an interdisciplinary approach

The immediate impact of the COVID-19 pandemic on motor neuron disease services and mortality in Scotland

SARS-CoV-2 infection of the central nervous system in a 14-month-old child: a case report of a complete autopsy

Multiple organ infection and the pathogenesis of SARS

Olfactory loss in Parkinson's disease

Neuropsychiatric and cognitive effects of the COVID-19 outbreak on multiple sclerosis patients

Clinical features and outcomes of patients with dementia compared to an aging cohort hospitalized during the initial New York City COVID-19 wave

Dementia and outcomes from coronavirus disease 2019 (COVID-19) pneumonia: a systematic review and meta-analysis

Neuroimmune multi-hit perspective of coronaviral infection

Immediate and long-term consequences of COVID-19 infections for the development of neurological disease

Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study

Viral mapping in COVID-19 deceased in the Augsburg autopsy series of the first wave: a multiorgan and multimethodological approach

Encephalitis lethargica: 100 years after the epidemic

Long-term health sequelae and quality of life at least 6 months after infection with SARS-CoV-2: design and rationale of the COVIDOMstudy as part of the NAPKON population-based cohort platform (POP)

Impact of COVID-19 pandemic on patients with neurodegenerative diseases

Fang F (2022) COVID-19 related outcomes among individuals with neurodegenerative diseases: a cohort analysis in the UK biobank

2021) 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study

Outcomes of SARS-CoV-2 infections in patients with neurodegenerative diseases in the LEOSS cohort

Increased incidence of functional (psychogenic) movement disorders in children and adults amid the COVID-19 pandemic: a cross-sectional study

Neurochemical signs of astrocytic and neuronal injury in acute COVID-19 normalizes during long-term follow-up

From Anti-SARS-CoV-2 immune response to the cytokine storm via molecular mimicry. Antibodies (basel)

Neurofilaments as biomarkers in neurological disorders

The architecture of SARS-CoV-2 transcriptome

Postencephalitic parkinsonism responsive to a dopamine agonist: a case report

Risk factors for neuropsychiatric symptoms in patients with Parkinson's disease during COVID-19 pandemic in Japan

Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus

Neuropsychiatric symptoms and quality of life in Spanish patients with Alzheimer's disease during the COVID-19 lockdown

Physical activity and perceived health in people with Parkinson disease during the first wave of Covid-19 pandemic: a cross-sectional study From Sweden

The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity

Infectious etiologies of Parkinsonism: pathomechanisms and clinical implications

Effectiveness of Covid-19 vaccines over a 9-month period in North Carolina

The impact of dementia on the clinical outcome of COVID-19: a systematic review and meta-analysis

Highly efficient intercellular spreading of protein misfolding mediated by viral ligand-receptor interactions

The reproductive number of COVID-19 is higher compared to SARS coronavirus

Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in

Clinical research disruption in the post-COVID-19 era: will the pandemic lead to change?

Consortium I (2021) Guillain-Barre syndrome after SARS-CoV-2 infection in an international prospective cohort study

Imaging of neurologic disease in hospitalized patients with COVID-19: an Italian multicenter retrospective observational Study

COVID-19-associated acute disseminated encephalomyelitis: a systematic review

Neurologic manifestations of hospitalized patients With Coronavirus Disease 2019 in Wuhan

Neuropathology of patients with COVID-19 in Germany: a post-mortem case series

Coronavirus disease 2019 and neurodegenerative disease: what will the future bring?

Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19

Delirium in older patients with COVID-19: prevalence, risk factors, and clinical relevance

Acute hypokinetic-rigid syndrome following SARS-CoV-2 infection

Frequency of neurologic manifestations in COVID-19: a systematic review and meta-analysis

A first case of meningitis/encephalitis associated with SARS-Coronavirus-2

MuSK antibody-associated myasthenia gravis with SARS-CoV-2 infection: a case report

Autoimmune encephalitis presenting with malignant catatonia in a 40-year-old male patient with COVID-19

Impact of the covid-19 pandemic on amyotrophic lateral sclerosis care in the UK

Assessment of the frequency and variety of persistent symptoms among patients with COVID-19: a systematic review

Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2

Cerebrospinal fluid findings in COVID-19 patients with neurological symptoms

COVID-19 rapid guideline: managing the long-term effects of COVID-19

Detachment of brain pericytes from the basal lamina is involved in disruption of the blood-brain barrier caused by lipopolysaccharide-induced sepsis in mice

Peripheral neuropathy evaluations of patients with prolonged long COVID

COVID-19-associated acute disseminated encephalomyelitis (ADEM)

Serum and cerebrospinal fluid biomarker profiles in acute SARS-CoV-2-associated neurological syndromes

COVID-19-associated acute hemorrhagic necrotizing encephalopathy: imaging features

Determinants of COVID-19-related lethality in multiple sclerosis: a meta-regression of observational studies

Serum neurofilament light protein correlates with unfavorable clinical outcomes in hospitalized patients with COVID-19

Brain imaging use and findings in COVID-19: a single academic center experience in the epicenter of disease in the United States

SARS-CoV-2 targets neurons of 3D human brain organoids

A longitudinal study of mental health before and during COVID-19 lockdown in the French population

Delirium in patients with SARS-CoV-2 infection: a multicenter study

Myasthenia gravis associated with SARS-CoV-2 infection

Analysis of nationwide multimodal complex treatment and drug pump therapy in Parkinson's disease in times of COVID-19 pandemic in Germany

Neurologic manifestations in 1760 COVID-19 patients admitted to Papa Giovanni XXIII Hospital

Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry

Covid-19 vaccine effectiveness in New York State

Galea I (2021) Spectrum, risk factors and outcomes of neurological and psychiatric complications of COVID-19: a UK-wide cross-sectional surveillance study

Delirium: clinical presentation and outcomes in older COVID-19 patients

Movement disorders associated with COVID-19

Clinical profiles and mortality of COVID-19 inpatients with Parkinson's disease in Germany

Acute transverse myelitis after SARS-CoV-2 infection: a rare complicated case of rapid onset paraplegia

Mental health, physical activity, and quality of life in Parkinson's disease during COVID-19 pandemic

Structural basis of receptor recognition by SARS-CoV-2

Is SARS-CoV-2 vaccination safe and effective for elderly individuals with neurodegenerative diseases?

Effects of COVID-19 on preclinical and clinical research in neurology: examples from research on neurodegeneration and Alzheimer's disease

Analysis of ACE2 genetic variability among populations highlights a possible link with COVID-19-related neurological complications

Dementia is an age-independent risk factor for severity and death in COVID-19

The substantia nigra is a major target for neurovirulent influenza A virus

Autoimmune and rheumatic manifestations associated with COVID-19 in adults: an updated systematic review

Effectiveness of Covid-19 vaccines in ambulatory and inpatient care settings

Decreasing mental wellbeing during the COVID-19 pandemic: a longitudinal study among Danes before and during the pandemic

Guillain-Barre syndrome associated with SARS-CoV-2

CoroNerve Study G (2020) Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study

Biomarkers for central nervous system injury in cerebrospinal fluid are elevated in COVID-19 and associated with neurological symptoms and disease severity

Prevalence of chemosensory dysfunction in COVID-19 patients: a systematic review and meta-analysis reveals significant ethnic differences

COVID-19 and psychosis risk: real or delusional concern?

Kumfor F (2022) The effects of the COVID-19 pandemic on neuropsychiatric symptoms in dementia and carer mental health: an international multicentre study

Long-term cerebral consequences of sepsis

SARS-CoV-2 and neurodegenerative diseases: what we know and what we don't

Selfreported symptoms of COVID-19, including symptoms most predictive of SARS-CoV-2 infection, are heritable twin res

Factors associated with COVID-19-related death using OpenSAFELY

Impact of the COVID-19 pandemic on patients with Parkinson's disease from the perspective of treating physicians-a nationwide cross-sectional study

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Advances in research on ACE2 as a receptor for 2019-nCoV

Angiotensin-converting enzyme 2 in the brain: properties and future directions

A human pluripotent stem cell-based platform to study SARS-CoV-2 tropism and model virus infection in human cells and organoids

C9orf72 intermediate repeats confer genetic risk for severe COVID-19 pneumonia independently of age

COVID-19 case fatality and Alzheimer's disease

COVID-19 case fatality and Alzheimer's disease

Coronavirus disease 2019 case fatality and Parkinson's disease

Sars-Cov-2: underestimated damage to nervous system

Myelin oligodendrocyte glycoprotein antibody-associated optic neuritis and myelitis in COVID-19

Clinical and autoimmune characteristics of severe and critical cases of COVID-19

Spudich S (2020) Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: a review